A Phase 1 interventional study of 14C Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide. This means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.
Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 15 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of \[14C\]-tirzepatide administered subcutaneously (SC).
Drug: 14C Tirzepatide
Administered SC.
Also known as: LY3298176
Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.
Time frame: Pre-dose and up to 63 days post-dose
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.
Time frame: Pre-dose and up to 63 days post-dose
Total Number of Metabolites
Total Number of Metabolites.
Time frame: Pre-dose and up to 63 days post-dose
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable).
Time frame: Pre-dose and up to 63 days post-dose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of tirzepatide.
Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
PK: Maximum Concentration (Cmax) of Tirzepatide
PK: Maximum Concentration (Cmax) of tirzepatide.
Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Total Radioactivity
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of Total Radioactivity. Total radioactivity is reported as hours\*nanogram equivalents per milliliter (h\*ng Eq/mL).
Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
PK: Maximum Concentration (Cmax) of Total Radioactivity
PK: Cmax of total radioactivity in plasma and whole blood. The Cmax of total radioactivity in plasma and whole blood are reported as nanogram equivalents per milliliter (ng Eq/mL).
Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
| Milestone | [14C]-Tirzepatide |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.
| Percentage of the total radioactive dose | [14C]-Tirzepatide |
|---|---|
| Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered | 49.56 ± 2.58 |
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.
| Percentage of the total radioactive dose | [14C]-Tirzepatide |
|---|---|
| Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered | 20.46 ± 2.05 |
Total Number of Metabolites.
| metabolites | [14C]-Tirzepatide |
|---|---|
| Plasma | 4 |
| Urine | 6 |
| Feces | 6 |
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable).
| Percentage of the total radioactive dose | [14C]-Tirzepatide |
|---|---|
| Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable) | 70.03 ± 1.98 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of tirzepatide.
| nanogram*hour per milliliter (ng*h/mL) | [14C]-Tirzepatide |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide | 96100 ± 13 |
PK: Maximum Concentration (Cmax) of tirzepatide.
| ng/mL | [14C]-Tirzepatide |
|---|---|
| PK: Maximum Concentration (Cmax) of Tirzepatide | 453 ± 29 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of Total Radioactivity. Total radioactivity is reported as hours\*nanogram equivalents per milliliter (h\*ng Eq/mL).
| h*ng Eq/mL | [14C]-Tirzepatide |
|---|---|
| Plasma | 87900 ± 13 |
| Whole blood | 44000 ± 11 |
PK: Cmax of total radioactivity in plasma and whole blood. The Cmax of total radioactivity in plasma and whole blood are reported as nanogram equivalents per milliliter (ng Eq/mL).
| ng Eq/mL | [14C]-Tirzepatide |
|---|---|
| Plasma | 327 ± 16 |
| Whole Blood | 173 ± 14 |
Collected over Up To Day 64. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| [14C]-Tirzepatide | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | [14C]-Tirzepatide |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 6/6 |
| PalpitationsCardiac disorders | 2/6 |
| NauseaGastrointestinal disorders | 1/6 |
| ToothacheGastrointestinal disorders | 1/6 |
| VomitingGastrointestinal disorders | 1/6 |
| Feeling of body temperature changeGeneral disorders | 1/6 |
| PresyncopeNervous system disorders | 1/6 |
All randomized participants.
| Age, Continuous(years) | [14C]-Tirzepatide |
|---|---|
| Mean | 41.0 ± 10.4 |
| Sex: Female, Male(Participants) | [14C]-Tirzepatide |
|---|---|
| Female | 0 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | [14C]-Tirzepatide |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | [14C]-Tirzepatide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | [14C]-Tirzepatide |
|---|---|
| United Kingdom | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Oct 2020, 2 months.
Results were first posted in Mar 2023, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide